Tags

Type your tag names separated by a space and hit enter

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Respir Med. 2003 Oct; 97(10):1134-42.RM

Abstract

BACKGROUND

IV/PO moxifloxacin was evaluated in the treatment of hospitalized patients with severe community-acquired pneumonia (CAP).

METHODS

Data were pooled from two prospective, randomized studies. In the multinational study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD or IV/ PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID. In the North American study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD, IV/ PO alatrofloxacin/trovafloxacin 200 mg QD, or IV/PO levofloxacin 500 mg QD. The primary endpoint was clinical success at the test-to-cure visit. Severe CAP was defined according to the 1993 ATS criteria.

RESULTS

In the clinically valid population, clinical success rates were 88% (167/190) for moxifloxacin- and 83% (155/186) for comparator-treated patients (95% CI = -1.9%, 12.2%). Corresponding clinical success rates for the microbiologically valid population were 87% (59/68) and 84% (54/64), respectively (95% CI = 8.6%, 15.0%). A switch from IV to PO therapy was made by day 5 of therapy for 73% of moxifloxacin- vs. 60% of comparator-treated patients (P < 0.01). Clinical success rates were similar in a retrospective analysis using the revised 2001 ATS definition of severe CAP. Mortality rates were 6% (15/241) and 10% (24/238) in the moxifloxacin and comparator treatment groups, respectively. The incidence of drug-related adverse events was similar in both treatment groups.

CONCLUSION

Sequential IV/PO moxifloxacin 400 mg QD is as safe and effective as other fluoroquinolones and a beta-lactam/macrolide combination for treating hospitalized patients with severe CAP.

Authors+Show Affiliations

Zentralklinik Emil von Behring, Lungenklinik Heckeshorn, Berlin 10115, Germany. haloheck@zedat.fu-berlin.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14561021

Citation

Lode, H, et al. "Sequential IV/PO Moxifloxacin Treatment of Patients With Severe Community-acquired Pneumonia." Respiratory Medicine, vol. 97, no. 10, 2003, pp. 1134-42.
Lode H, Grossman C, Choudhri S, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med. 2003;97(10):1134-42.
Lode, H., Grossman, C., Choudhri, S., Haverstock, D., McGivern, J., Herman-Gnjidic, Z., & Church, D. (2003). Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respiratory Medicine, 97(10), 1134-42.
Lode H, et al. Sequential IV/PO Moxifloxacin Treatment of Patients With Severe Community-acquired Pneumonia. Respir Med. 2003;97(10):1134-42. PubMed PMID: 14561021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. AU - Lode,H, AU - Grossman,C, AU - Choudhri,S, AU - Haverstock,D, AU - McGivern,J, AU - Herman-Gnjidic,Z, AU - Church,D, PY - 2003/10/17/pubmed PY - 2003/12/13/medline PY - 2003/10/17/entrez SP - 1134 EP - 42 JF - Respiratory medicine JO - Respir Med VL - 97 IS - 10 N2 - BACKGROUND: IV/PO moxifloxacin was evaluated in the treatment of hospitalized patients with severe community-acquired pneumonia (CAP). METHODS: Data were pooled from two prospective, randomized studies. In the multinational study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD or IV/ PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID. In the North American study, patients received 7-14 days IV/PO moxifloxacin 400 mg QD, IV/ PO alatrofloxacin/trovafloxacin 200 mg QD, or IV/PO levofloxacin 500 mg QD. The primary endpoint was clinical success at the test-to-cure visit. Severe CAP was defined according to the 1993 ATS criteria. RESULTS: In the clinically valid population, clinical success rates were 88% (167/190) for moxifloxacin- and 83% (155/186) for comparator-treated patients (95% CI = -1.9%, 12.2%). Corresponding clinical success rates for the microbiologically valid population were 87% (59/68) and 84% (54/64), respectively (95% CI = 8.6%, 15.0%). A switch from IV to PO therapy was made by day 5 of therapy for 73% of moxifloxacin- vs. 60% of comparator-treated patients (P < 0.01). Clinical success rates were similar in a retrospective analysis using the revised 2001 ATS definition of severe CAP. Mortality rates were 6% (15/241) and 10% (24/238) in the moxifloxacin and comparator treatment groups, respectively. The incidence of drug-related adverse events was similar in both treatment groups. CONCLUSION: Sequential IV/PO moxifloxacin 400 mg QD is as safe and effective as other fluoroquinolones and a beta-lactam/macrolide combination for treating hospitalized patients with severe CAP. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/14561021/Sequential_IV/PO_moxifloxacin_treatment_of_patients_with_severe_community_acquired_pneumonia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(03)00166-5 DB - PRIME DP - Unbound Medicine ER -